For All The Palace Intrigue, Rebate Rule, IPI Go To OMB For Review
Executive Summary
For all the rumors of political infighting, the two cornerstones of the Trump administration’s blueprint on drug pricing are in the final phase for review.
You may also be interested in...
Pharma's Big Defeat: US Rebate Proposal Hits The End Of The Road
White House will not move forward with a rebate proposal the drug industry supported as a way to lower patient drug spending.
Pharma's Big Defeat: US Rebate Proposal Hits The End Of The Road
White House will not move forward with a rebate proposal the drug industry supported as a way to lower patient drug spending.
White House Exec Order Will Bring US Parity With Lowest Drug Prices Abroad, Trump Says
Remarks to reporters prompt surprise and confusion among stakeholders and likely reflect the president’s impatience with the pace of regulatory and legislative pricing reforms.